Infectious Diseases Clinical Trial
— EPPOfficial title:
Incidence of Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics Lactobacillus Boucardii.
Verified date | August 2014 |
Source | Coordinación de Investigación en Salud, Mexico |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to know the effects of probiotics on the incidence of Necrotizing Enterocolitis (NEC) in preterm infants less than 1500 g.
Status | Completed |
Enrollment | 150 |
Est. completion date | February 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 27 Weeks to 34 Weeks |
Eligibility |
Inclusion Criteria: - We studied 150 preterm newborns <1500gr who were recruited on the day that began enteral feeding according to the decision of the treating physician. Exclusion Criteria: - Preterm infants > 1500g with Apgar score <6 at 5 minutes, gastrointestinal malformations, fetopathies, patent ductus arteriosis with hemodynamic decompensation, asphyxia, and NEC suspected as classified by Bell were excluded from the study. |
Country | Name | City | State |
---|---|---|---|
Mexico | Instituto Mexicano del seguro social | Leon | Guanajuato |
Lead Sponsor | Collaborator |
---|---|
Coordinación de Investigación en Salud, Mexico |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Diagnosis the Necrotizing Enterocolitis (NEC) | Our primary outcome was the presence of severe (NEC) monitored by the Bell´s criteria; secondarily we evaluated the presence of sepsis diagnosed with clinical signs of systemic inflammatory response and positive blood culture, | 23 month | |
Primary | Incidence of severe necrotizing enterocolitis in preterm newborns <1500g | Group A received enteral stimulation trophic five days and later increments 20ml/k/day of breast milk or formula for premature; the group B apart from the above the probiotic Lactobacillus boucardii 1 X109 (CFU) / day for 4 weeks was added. | 23 month | |
Secondary | Adverse effects with probiotic use in preterm newborns <1500g. | The amount of food was increased slowly if tolerated according to the Clinical Practice Guidelines for enteral feeding preterm in our hospital, enteral feeding was interrupted if there was any sign of intolerance such as vomiting, presence of bile or blood content by probe orogastric, bloating, or bloody stools which were assessed and recorded daily.Our primary outcome was the presence of severe necrotizing enterocolitis (NEC) monitored by the Bell´s criteria; secondarily we evaluated the presence of sepsis diagnosed with clinical signs of systemic inflammatory response and positive blood culture. | 23 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02763345 -
The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi
|
N/A | |
Completed |
NCT00550706 -
Drug Utilization Prevalence in a Pediatric Care Medical Center
|
N/A | |
Completed |
NCT01033799 -
Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers
|
N/A | |
Completed |
NCT00761462 -
BAY 0 9867 Cipro Pediatric Use Study (QUIP)
|
Phase 3 | |
Completed |
NCT05088421 -
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00828971 -
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs
|
Phase 3 | |
Completed |
NCT05468723 -
Evaluating Patient Comfort and Environmental Conditions in the Carecube Negative Pressure Isolation Chamber.1
|
||
Recruiting |
NCT02162966 -
Safety and Efficacy Study of High Dose Colistin
|
Phase 4 | |
Recruiting |
NCT00001281 -
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
|
||
Active, not recruiting |
NCT02654210 -
LoewenKIDS - Infections and the Development of the Immune System
|
||
Terminated |
NCT00211471 -
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).
|
Phase 2 | |
Active, not recruiting |
NCT04342702 -
A Study on the Prospective Cohort Library of COVID-19 in Southeran
|
||
Completed |
NCT02134548 -
Sensitivity Study of Diagnostic for Detection of Chagas Infection
|
N/A | |
Active, not recruiting |
NCT01611025 -
Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time
|
N/A | |
Completed |
NCT01361997 -
Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination
|
Phase 3 | |
Completed |
NCT00638677 -
Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier
|
Phase 4 | |
Completed |
NCT02434848 -
A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses
|
Phase 2/Phase 3 | |
Completed |
NCT02544139 -
Specificity Study of Diagnostic for Chagas Disease
|
N/A | |
Completed |
NCT00276198 -
Efficacy Trial to Examine Efficacy of Multimicronutrient Home Supplementation in Infants
|
Phase 3 | |
Completed |
NCT02111564 -
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
|
Phase 3 |